Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000986548 | SCV001135567 | likely pathogenic | Usher syndrome type 2A | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001869337 | SCV002232785 | pathogenic | not provided | 2022-06-13 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly516 amino acid residue in USH2A. Other variant(s) that disrupt this residue have been observed in individuals with USH2A-related conditions (PMID: 27460420), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 801619). This missense change has been observed in individuals with Usher syndrome (PMID: 15325563, 21738395, 27460420, 33576794). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 516 of the USH2A protein (p.Gly516Val). |
Genome- |
RCV000986548 | SCV004182860 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003467540 | SCV004208269 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-28 | criteria provided, single submitter | clinical testing |